placebo + lonafarnib

This is a combination used in clinical trials where one group receives the active drug lonafarnib and another group receives a placebo, allowing for comparison of efficacy and safety. Lonafarnib is a farnesyltransferase inhibitor used to reduce mortality in patients with Hutchinson-Gilford progeria syndrome (HGPS) and certain processing-deficient progeroid laminopathies. It works by inhibiting the farnesylation of proteins such as progerin, preventing their accumulation and subsequent cellular damage[1][2][5]. The term "placebo + lonafarnib" does not refer to a single product but rather to two separate arms within a clinical trial or study design.

Other names

placebo and lonafarniblonafarnib plus placebo